Members Login
Channels
Special Offers & Promotions
Protagen and VELA Form Strategic Partnership
publication date: Sep 19, 2011
|
author/source: Protagen
Vela Laboratories, Vienna,
one of the leading companies in the area of GMP-compliant potency and release
testing of Biopharmaceuticals, and Protagen AG,
Dortmund, a GMP-certified specialist in the characterization of protein drugs
form a strategic alliance in customer based analytics and marketing &
sales.
"The fast growing demand for Comparability of Biologics needs creative steps and business models. Protagen and VELA are internationally renowned and well-established contract research labs for complete characterization of Biopharmaceuticals and Biosimilars, and both companies belong to the leading providers of ICH-compliant analytical services. Our customers will benefit from this alliance through more efficient project work and study design", states Dr. Markus Fido, CEO of VELA Laboratories.
"The technology portfolio and the exceptional expertise of VELA in the area of bioassays for potency determination of therapeutic antibodies, growth factors and protein hormones, will synergistically complement the experience and competences of Protagen. Our customers in the pharmaceutical and biotech sector as well as CROs and CMOs will profit from this alliance through the direct access to a comprehensive service portfolio", comments Dr. Stefan Müllner, CEO of Protagen AG.
"The fast growing demand for Comparability of Biologics needs creative steps and business models. Protagen and VELA are internationally renowned and well-established contract research labs for complete characterization of Biopharmaceuticals and Biosimilars, and both companies belong to the leading providers of ICH-compliant analytical services. Our customers will benefit from this alliance through more efficient project work and study design", states Dr. Markus Fido, CEO of VELA Laboratories.
"The technology portfolio and the exceptional expertise of VELA in the area of bioassays for potency determination of therapeutic antibodies, growth factors and protein hormones, will synergistically complement the experience and competences of Protagen. Our customers in the pharmaceutical and biotech sector as well as CROs and CMOs will profit from this alliance through the direct access to a comprehensive service portfolio", comments Dr. Stefan Müllner, CEO of Protagen AG.
Media Partners